Aytu BioScience Inc.
AYTU
NSC
Sector: Healthcare
Industry: Biotechnology
0.56
USD
0.03
(6.18%)
Optionable: Yes Market Cap: 20 M 90-day average vol: 0
Previous close: 0.5274 Open: 0.52 Bid: 0.57 Ask: 0.57
52 week range
0.00 0.00
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Chart
News
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
Yahoo Finance 3/3/2022
Aytu Biopharma's AR101 for tissue disorder gets orphan status in Europe
Seeking Alpha 3/2/2022
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
Yahoo Finance 3/2/2022
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
Yahoo Finance 2/18/2022
Aytu BioScience GAAP EPS of -$0.44 beats by $0.14, revenue of $23.13M misses by $4.07M
Seeking Alpha 2/14/2022
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
Yahoo Finance 2/14/2022
Aytu BioPharma Completes $15 Million Debt Refinancing
Yahoo Finance 1/31/2022
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
Yahoo Finance 1/4/2022
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
Yahoo Finance 1/3/2022
Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome
Yahoo Finance 12/14/2021
FDA greenlights clinical trial for Aytu's VEDS drug candidate
Seeking Alpha 12/13/2021
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
Yahoo Finance 12/13/2021
Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status
Yahoo Finance 12/9/2021
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
Yahoo Finance 12/8/2021
Aytu BioPharma announces patent win for experimental respiratory device, Healight
Seeking Alpha 11/23/2021
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!